Zahraa Amer Hashim

Zahraa Amer Hashim

Auto-generated profile, based on publicly available information

Zahraa Amer Hashim

University of Mosul

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in European Journal of Oral Sciences
Verified
Journal Article
Open access
ZHZahraa Amer Hashim
Zahraa Amer Hashim
JMJean-Yves Maillard
Jean-Yves Maillard
MWMelanie Jay Wilson
Melanie Jay Wilson
RWRachel Jane Waddington
Rachel Jane Waddington
Microbial biofilms play a dominant role in the failure of endodontic therapies. Bacterial adhesion is the first step in the establishment of biofilms, activating the host immune response leading to tissue damage. Biosurfactants are microbe‐derived tensioactive molecules with latent anti‐adhesive and anti‐microbial activity. This study reports the extraction and characterization of a biosurfactant from Lactobacillus (L.) plantarum (Lp‐BS) and investigates its anti‐microbial and anti‐adhesive properties compared to rhamnolipid, a commercially available biosurfactant. Lp‐BS, extracted from L. plantarum during the growth phase, was characterized as a glycoprotein, able to reduce surface tension and emulsify non‐polar liquids. Proteomic analysis of Lp‐BS identified three bacterial adhesin‐like proteins, suggesting roles in hindering bacterial adhesion. Lp‐BS did not show significant anti‐microbial activity against endodontic pathogens from the Streptococcus (Strep.) anginosus group or Enterococcus (Ent.) faecalis at 50 mg/ml. However, anti‐adhesive activity on abiotic surfaces was observed against both Strep. anginosus and Strep. intermedius. Rhamnolipid exhibited strong anti‐microbial activity, with minimum inhibitory concentrations of 0.097 mg/ml against Strep. anginosus, and 0.048 mg/ml against Strep. constellatus and Strep. intermedius, in addition to a marked anti‐adhesive activity. These findings offer preliminary evidence for the potential application of biosurfactants as an anti‐microbial and/or anti‐adhesive pharmacotherapy in endodontics.

1 January 2022 in Journal of Research in Pharmacy
Verified
Journal Article
Closed access
ZHZahraa Amer Hashim
Zahraa Amer Hashim
ZQZahraa Sedeeq Qasim
Zahraa Sedeeq Qasim


19 March 2024 in Microbes and Infectious Diseases
Verified
Journal Article
Closed access
ZHZahraa Amer Hashim
Zahraa Amer Hashim
VCVildan Celiksoy
Vildan Celiksoy
Pharmaceutical products’ microbial contamination is a serious worry in the pharmaceutical industry, as it can posture momentous health jeopardies to patients. Contamination with microbes can befall at any stage of manufacturing, starting with raw materials and ending with the finished products. It can also result from a variety of sources counting the environment, working personnel and equipment used. Common microorganisms that contaminate pharmaceutical products include bacteria, fungi, and viruses. The presence of these contaminants can compromise the quality, safety, and efficacy of pharmaceutical products, leading to product recalls, loss of reputation, and financial losses. Therefore, it is essential for pharmaceutical manufacturers to implement robust quality control measures to detect and prevent microbial contamination, including stringent cleaning and sanitation procedures, environmental monitoring, and microbiological testing. In this review, we discussed the main conventional and advanced technologies of detecting microbial contamination in pharmaceutical products. These techniques range from conventional culture methods to the more sophisticated technologies of gene sequencing and spectroscopy.

11 January 2026 in Journal of Research in Pharmacy
Verified
Journal Article
Closed access
ZKZainab Abdullah Khaleel
Zainab Abdullah Khaleel
ZHZahraa Amer Hashim
Zahraa Amer Hashim
VCVildan Celiksoy
Vildan Celiksoy
Urinary tract infection (UTI) and vaginitis are common conditions among females, significantly impacting overall life health and quality, imposing economical burdens and rising concerns of antibiotic resistance and limiting current treatments, probiotics have emerged as promising non antibiotic adjuvant and alternatives. Lactobacillus species restore and sustain a balanced microbiome offering protection against uro-pathogens by enhancement of epithelium barrier, immune modulation, competitive exclusions and biofilm disruptions. Clinical trials have documented the efficacy of probiotics both orally and vaginally in reducing UTI, preventing recurrences and restoring vaginal microbiota. This review highlights the aspects of probiotics mechanism of action, clinical trials and applications, exploring potentials of next generation probiotics and advancement in in delivery systems. While probiotics offer promising efficacy in managing UTI and vaginitis, further research studies are required to clarify exact mechanisms, strains potentials, dosage forms and doses, framing regulations regarding probiotics industry and tailored probiotics field.

8 March 2023 in Pharmacia
Verified
Journal Article
Open access
PDF file
KAKaram A. Aldabbagh
Karam A. Aldabbagh
ZHZahraa Amer Hashim
Zahraa Amer Hashim
ZQZahraa Sedeeq Qasim
Zahraa Sedeeq Qasim
Of the factors predisposing to gastric cancer is Helicobacter pylori infection affecting more than 50% of the general population. Genetic variation is an established player in certain diseases susceptibility. TAS2R38 gene polymorphisms have been found to influence bitter taste ability to chemicals with malicious characteristics and consequently affect metabolism and disease development. This study aimed to investigate the correlation between TAS2R38 gene polymorphisms and H. pylori seropositivity. The study involved 105 apparently healthy individuals. They were grouped into four groups according to their age and gender; young male, young female, middle-aged male and middle-aged female. All groups were tested for H. pylori serum antibody using screening rapid test. Participants were also tested for tasting PTC for TAS2R38 gene detection by using Bartovation PTC test paper and grouped accordingly into: homozygote (highly bitter taste), heterozygote (slight to moderate bitter taste), or negative gene carrier (no taste at all). ABO and Rhesus- blood grouping was determined by standard serological analysis. Of the 105 patients, 22.85% were tested homozygotes for TAS2R38 gene, 40.95% were heterozygotes and 36.19% were nontasters, no significant difference (p > 0.9). H. pylori seropositivity was encountered in 16.19% of the whole participants, 11.5% of the male participants and 20.75% of the female participants (p > 0.9). No significant difference in seropositivity was monitored among the four age groups (p > 0.3) and the ABO/Rh blood groups (p > 0.9). A lack of significant correlation (r = 0.046) between H. pylori antibody test positivity and tasting PTC (TAS2R38 gene) was reported. Similarly, no association was found between PTC tasting and participants’ ABO blood grouping, age or gender (r = 0.086, 0.083 and 0.029, respectively). Yet, weak negative (reverse) relationship (r = -0.29, p-value = 0.002) was gained between PTC and Rh grouping. No correlation was revealed between TAS2R38 polymorphism and the studied variable; age, gender and blood group indicating the absence of an apparent role of the gene in vulnerability to H. pylori infection. Further studies involving a larger sample size is required to confirm the obtained result.